Winton Matthew — SEC Form 4 filings
SEC reporting owner CIK 1971400. 11 Form 4 filings on record with FilingPulse; latest filed 2026-02-13.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-03-15 to 2026-02-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 15,000 shares, $117,130 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: purchase of 10,000 shares @ $7.57 ($75,700) in CervoMed Inc., filed 2025-11-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CervoMed Inc. (CRVO) | Chief Commercial and Business | 4 | 3 legs · 15,000 sh · $117,130 | — | 2 |
| Inozyme Pharma, Inc. (INZY) | COO | 7 | — | — | 10 |
Form 4 filings — Winton Matthew
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-13 | 4 | CervoMed Inc. (CRVO) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | CervoMed Inc. (CRVO) | Purchase (P): 3,500 @ $8.43 · Purchase (P): 1,500 @ $7.95 | EDGAR |
| 2025-11-17 | 4 | CervoMed Inc. (CRVO) | Purchase (P): 10,000 @ $7.57 | EDGAR |
| 2025-10-08 | 4 | CervoMed Inc. (CRVO) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Inozyme Pharma, Inc. (INZY) | Code (U): 21,743 @ $4 · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2025-06-27 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 14,355 @ $0.74 | EDGAR |
| 2025-04-02 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 2,490 @ $0.77 | EDGAR |
| 2025-03-17 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 1,710 @ $4.45 | EDGAR |
| 2024-04-03 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 3,188 @ $3.33 | EDGAR |
| 2024-03-15 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1971400 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →